Skip to main content

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo! Finance
JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to five new employees to purchase an aggregate of 24,500 shares of SCYNEXIS common stock at a per share exercise price of $6.97, the closing trading price on July 30, 2021. The stock options were granted as material inducements to the new
Continue Reading